$ABSI News

Truist Securities Maintains Buy on Absci, Raises Price Target to $17

Absci Raises $100 Million In Equity To Fund AI-Designed Hair Loss And Endometriosis Program

HC Wainwright & Co. Maintains Buy on Absci, Raises Price Target to $16

Needham Reiterates Buy on Absci, Raises Price Target to $11

Absci: Eli Lilly Backs Alopecia Data With Funding, But Risks Remain

BTIG Maintains Buy on Absci, Raises Price Target to $13

Absci Shares Soar After Positive Early Clinical Results for Hair Loss Therapy (ABSI)

Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR)

Absci Raises $100 Million In Equity To Fund AI-Designed Hair Loss And Endometriosis Program

Absci Prices $100M Underwritten Offering Of 13,495,277 Shares At $7.41 Per Share

Absci Announces Interim Phase 1 Data From Its Trial Of ABS-201, An Investigational Anti-Prolactin Receptor Antibody; Study Medication Appears Well Tolerated, With Favorable Safety Data Across All Blinded Single Ascending Dose Cohorts

Guggenheim is Bullish on Absci Corporation (ABSI)

Is Absci Corporation (ABSI) A Good Stock To Buy Now?

Leerink Starts Coverage on Absci Corporation (ABSI)

Guggenheim Maintains Buy on Absci, Raises Price Target to $15

MindWalk (NASDAQ: HYFT) CEO Dr. Jennifer Bath to Join Absci (NASDAQ: ABSI) and a Leading AI Compute Provider on Jones AI Day Panel on the Future of AI Drug Discovery

Absci Corporation (ABSI) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Slideshow

Absci Corporation (ABSI) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Prepared Remarks Transcript

Absci Corporation: A Big Binary Approaching In Alopecia

Absci Corporation (ABSI) Presents at Jefferies Global Healthcare Conference 2026 Prepared Remarks Transcript